Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
- Conditions
- Locally Advanced Thymoma
- Interventions
- Radiation: neoadjuvant radiotherapy
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 178
- Registration Number
- NCT06924619
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
- Conditions
- Extrahepatic CholangiocarcinomaPerihilar CholangiocarcinomaDistal CholangiocarcinomaResectableBorderline Resectable
- Interventions
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 150
- Registration Number
- NCT06923475
- Locations
- 🇳🇱
Amsterdam University Medical Center, Amsterdam, Netherlands
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT06916494
- Locations
- 🇨🇳
First Affiliated Hospital of Chongqing Medical University, ChongQing, Chongqing, China
Probiotics in Advanced Urothelial Carcinoma
- Conditions
- ProbioticsAdvanced Urothelial CarcinomaImmunotherapy
- Interventions
- Drug: Probiotics Compound (Biolosion)Drug: Enfortumab Vedotin
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 222
- Registration Number
- NCT06904573
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳Sun yat-sen university cancer center, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerRecurrent Breast Cancer
- Interventions
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 20
- Registration Number
- NCT06900647
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
- Conditions
- NSCLC (advanced Non-small Cell Lung Cancer)Stage IV Lung Cancer
- Interventions
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Inhatarget Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT06896890
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitario La PAZ, IdiPAZ, Madrid, Spain
🇪🇸Hospital Universitario Virgen del Rocío, Seville, Spain
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
- Conditions
- Combined Hepatocellular and Cholangiocarcinoma
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Mehmet Akce
- Target Recruit Count
- 29
- Registration Number
- NCT06855225
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
- Conditions
- Head and Neck Cancers
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT06894459
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT06875310
- Locations
- 🇲🇽
Local Institution - 0638, Puebla, Mexico
🇧🇪Local Institution - 0215, Hasselt, Limburg, Belgium
🇲🇽Local Institution - 0181, Puebla, Mexico
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
- Conditions
- Advanced Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06858735
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.